Ketamine treatment for depression: qualitative study exploring patient views
Sagar Jilka, Clarissa Mary Odoi, Emma Wilson, Sazan Meran, Sara Simblett, Til Wykes
BJPsych Open 2021 DOI: 10.1192/bjo.2020.165 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 14 |
| Population | Patients with prior diagnoses of depression but no experience of ketamine treatment |
| Topics | Depression Esketamine Ketamine |
| Key findings | Participants were enthusiastic about ketamine treatment for depression but wanted more information, including evidence on long-term safety, before national roll-out. They saw monitoring as necessary to support safe use while raising concerns about misuse of the resulting information, and they wanted patients involved in any future roll-out. |
Abstract
Background: Ketamine is a new and promising treatment for depression but comes with challenges to implement because of its potential for abuse.
Aims: We sought the views of patients to inform policy and practical decisions about the clinical use of ketamine before large-scale roll-out is considered.
Method: This qualitative study used three focus groups and three validation sessions from 14 patients with prior diagnoses of depression but no experience of ketamine treatment. Focus groups explored their views about clinical use of ketamine and the best way for ketamine to be administered and monitored. The qualitative data were analysed by three service-user researchers using thematic analysis.
Results: Five themes were generated: changing public perceptions, risks, monitoring, privacy and data protection, and practical aspects. Participants were conscious of the stigma attached to ketamine as a street drug and wanted better public education, and evidence on the safety of ketamine after long-term use. They felt that monitoring was required to provide evidence for ketamine's safe use and administration, but there were concerns about the misuse of this information. Practical aspects included discussions about treatment duration, administration and accessibility (for example who would receive it, under what criteria and how).
Conclusions: Patients are enthusiastic about ketamine treatment but need more information before national roll-out. The wider societal impact of ketamine treatment also needs to be considered and patients need to be part of any future roll-out to ensure its success.
Comparable studies
Other qualitative studies on ketamine for depression, most cited first.
Citations in the library
Cited by 20
- Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. Frontiers in Psychiatry 2022
- Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review Journal of Psychedelic Studies February 5, 2024
- Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology July 1, 2023
- Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022. Journal of Affective Disorders March 15, 2025
- A systematic review of the print media representation of ketamine treatments for psychiatric disorders BJPsych Open June 7, 2023
and 15 more in the library
Cites 8
- Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Psychological Medicine February 12, 2016
- Ketamine and depression: a narrative review Drug Design, Development and Therapy August 1, 2019
- Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry April 5, 2017
- From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine CNS Neuroscience & Therapeutics June 1, 2013
- Ketamine: stimulating antidepressant treatment? BJPsych Open May 1, 2016
and 3 more in the library